BioWorld

June 18, 2003

View Archived Issues

MedImmune's Intranasal Vaccine FluMist Receives FDA Approval

MedImmune Inc. received long-awaited news late Tuesday afternoon as the FDA approved FluMist, a nasally delivered product that has ridden a rocky road throughout the regulatory review process. (BioWorld Today) Read More

Cell Therapeutics, Novuspharma Merging In $236M Stock Exchange

Read More

Alcohol Abuse In Pregnancy Can Bring On Fetal Alcohol Syndrome, Mental Retardation In The Young

Read More

Biomira, Merck KGaA Report Failed Theratope Phase III Trial

Read More

BioMarin Aiming To Raise $125M In Convertible Notes

Read More

Questcor Raises $5M To Fund $18.2M Purchase Of Nascobal

Read More

Boston Life Sciences Plans Another Altropane Phase III

Read More

Amylin Sends Symlin Amendment To FDA, Seeks $150M In Notes

Read More

Other News To Note

Read More